Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) is rising steadily in incidence, and more effective methods are needed for early detection and image-guided surgery. Glypican-3 (GPC3) is a cell surface biomarker that is overexpressed in early-stage cancer but not in cirrhosis. An IRDye800-labeled 12-mer amino acid sequence was identified, and specific binding to GPC3 was validated in vitro and in orthotopically implanted HCC tumors in vivo. Over 4-fold greater binding affinity and 2-fold faster kinetics were measured by comparison with previous GPC3 peptides. Photoacoustic images showed peak tumor uptake at 1.5 h post-injection and clearance within ∼24 h. Laparoscopic and whole-body fluorescence images showed strong intensity from tumor versus adjacent liver with about a 2-fold increase. Immunofluorescence staining of human liver specimens demonstrated specific binding to HCC versus cirrhosis with 79% sensitivity and 79% specificity, and normal liver with 81% sensitivity and 84% specificity. The near-infrared peptide is promising for early HCC detection in clinical trials.

[1]  Seth D. Crockett,et al.  Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. , 2021, Gastroenterology.

[2]  Jie Tian,et al.  Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery , 2020, Bioengineering & translational medicine.

[3]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[4]  V. Prasad.  Our best weapons against cancer are not magic bullets , 2020, Nature.

[5]  Thomas D. Wang,et al.  Integrated Imaging Methodology Detects Claudin-1 Expression in Premalignant Nonpolypoid and Polypoid Colonic Epithelium in Mice , 2020, Clinical and translational gastroenterology.

[6]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[7]  S. Bangaru,et al.  Review article: new therapeutic interventions for advanced hepatocellular carcinoma , 2019, Alimentary pharmacology & therapeutics.

[8]  H. Suga,et al.  Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges. , 2019, Journal of the American Chemical Society.

[9]  Jennifer L Lund,et al.  Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. , 2019, Gastroenterology.

[10]  Zhiyuan Hu,et al.  Targeting Peptide‐Based Probes for Molecular Imaging and Diagnosis , 2018, Advanced materials.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  Ozlem Kutlu,et al.  Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma , 2018, Canadian journal of gastroenterology & hepatology.

[13]  Takeaki Ishizawa,et al.  Fluorescence‐guided surgery for liver tumors , 2018, Journal of surgical oncology.

[14]  Caleb F. Anderson,et al.  Peptide-based nanoprobes for molecular imaging and disease diagnostics. , 2018, Chemical Society reviews.

[15]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[16]  Xiaoling Yu,et al.  Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment , 2018, Medicinal research reviews.

[17]  J. Wilton,et al.  Can intra-operative fluorescence play a significant role in hepatobiliary surgery? , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  J. Dufour,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma. , 2017, Hepatic oncology.

[19]  Justin R. Caram,et al.  Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green , 2017, Proceedings of the National Academy of Sciences.

[20]  Shi Gao,et al.  Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection. , 2017, Macromolecular bioscience.

[21]  F. Theil,et al.  Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins , 2016, Journal of immunology research.

[22]  T. Ishizawa,et al.  Clinical application of indocyanine green-fluorescence imaging during hepatectomy. , 2016, Hepatobiliary surgery and nutrition.

[23]  Sijuan Zou,et al.  Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. , 2016, Bioconjugate chemistry.

[24]  Lijun Xue,et al.  Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers. , 2015, Carcinogenesis.

[25]  N. Bardeesy,et al.  Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. , 2014, Journal of hepatology.

[26]  Mitchell Ho,et al.  Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican‐3 for liver cancer therapy , 2014, Hepatology.

[27]  Katsuhisa Horimoto,et al.  Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. , 2013, Genomics.

[28]  Hui-lai Miao,et al.  Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down‐regulation of YAP , 2013, Journal of cellular biochemistry.

[29]  U. Nöthlings,et al.  Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort , 2013, International journal of cancer.

[30]  Thomas D. Wang,et al.  Near-infrared-labeled peptide multimer functions as phage mimic for high affinity, specific targeting of colonic adenomas in vivo (with videos). , 2012, Gastrointestinal endoscopy.

[31]  Sang-Woo Lee,et al.  Targeting of hepatocellular carcinoma with glypican‐3‐targeting peptide ligand , 2011, Journal of peptide science : an official publication of the European Peptide Society.

[32]  Triantafyllos Stylianopoulos,et al.  Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.

[33]  Stephanie Roessler,et al.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. , 2010, Cancer research.

[34]  Seulki Lee,et al.  Peptides and peptide hormones for molecular imaging and disease diagnosis. , 2010, Chemical reviews.

[35]  Liping Yu,et al.  Targeted Drug Delivery to Hepatocarcinoma In vivo by Phage-Displayed Specific Binding Peptide , 2010, Molecular Cancer Research.

[36]  F. Zoulim,et al.  Hepatitis B virus induced hepatocellular carcinoma. , 2009, Cancer letters.

[37]  R. Juliano,et al.  Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[38]  T. Hasebe,et al.  Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. , 2009, International journal of oncology.

[39]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[40]  Chien-Hsun Wu,et al.  A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer , 2009, PloS one.

[41]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[42]  K Dane Wittrup,et al.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. , 2008, Advanced drug delivery reviews.

[43]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[44]  Chin-Tarng Lin,et al.  Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery , 2008, Molecular Cancer Therapeutics.

[45]  Robert A. Goulart,et al.  Glypican‐3 immunocytochemistry in liver fine‐needle aspirates , 2007, Cancer.

[46]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[47]  T. Roskams,et al.  Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas From Cirrhosis, Dysplastic Nodules, and Focal Nodular Hyperplasia-like Nodules , 2006, The American journal of surgical pathology.

[48]  V. Paradis,et al.  Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. , 2006, Human pathology.

[49]  Hiroyuki Aburatani,et al.  The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma , 2005, Modern Pathology.

[50]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[51]  H. Ghandehari,et al.  Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  C. Lobe,et al.  Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. , 2005, Cancer research.

[53]  John Sidney,et al.  Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.

[54]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[55]  B. Bray.  Large-scale manufacture of peptide therapeutics by chemical synthesis , 2003, Nature Reviews Drug Discovery.

[56]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[57]  S. Selleck,et al.  Glypicans: proteoglycans with a surprise. , 2001, The Journal of clinical investigation.

[58]  W. Semmler,et al.  Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands , 2001, Nature Biotechnology.

[59]  S. Achilefu,et al.  Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. , 2000, Investigative radiology.

[60]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[61]  S. K. Rudolph,et al.  Immunogenicity of Thrombopoietin Mimetic Peptide GW395058 in BALB/c Mice and New Zealand White Rabbits: Evaluation of the Potential for Thrombopoietin Neutralizing Antibody Production in Man , 1999, Stem cells.

[62]  R. Vessella,et al.  In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues , 2008, Clinical & Experimental Metastasis.

[63]  Hans-Jü Rgen Wester.  Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? , 2005 .